研究重组牛碱性成纤维细胞生长因子滴眼液治疗角膜病患者的效果

To Investigate the Efficacy of Recombinant Bovine Basic Fibroblast Growth Factor(BFGF)Eye Drops in the Treatment of Patients With Corneal Disease

目的探讨重组牛碱性成纤维细胞生长因子滴眼液应用于临床治疗角膜病患者的可行性。方法以本院2018年7月—2019年7月收治的角膜病患者76例为研究对象,按随机非盲法分为两组各38例,对照组予以常规药物治疗,观察组在此基础上加以重组牛碱性成纤维细胞生长因子滴眼液治疗,对比两组患者临床疗效及并发症发生率。结果观察组患者治疗有效率较对照组明显高(97.22%:77.78%,P<0.05),并发症发生率较对照组明显低(5.56%:44.44%,P<0.05),对比差异具有统计学意义。结论重组牛碱性成纤维细胞生长因子滴眼液在治疗角膜病患者中具有较高的可行性,可提高患者治疗有效率,改善患者临床症状及预后,降低并发症发生率,有较高的借鉴价值和应用前景。

Objective To investigate the feasibility of Beifushu eye drops in the treatment of keratopathy.Methods 76 patients with keratopathy in our hospital from July 2018 to July 2019 were divided into two groups randomly and non-blindly.The control group was treated with routine drugs,and the observation group was treated with Befushu eye drops on the basis of routine drugs.The clinical efficacy and the incidence of complications were compared between the two groups.Results The effective rate of treatment in the observation group was significantly higher than that in the control group(97.22%;77.78%,P<0.05),and the incidence of complications was significantly lower than that in the control group(5.56%;44.44%,P<0.05).Conclusion Beifushu eye drops have high feasibility in the treatment of patients with keratopathy.It can improve the efficiency of treatment,improve the clinical symptoms and prognosis of patients,and reduce the incidence of complications.It has high reference value and application prospects.